Browsing Tag
RSV vaccine
7 posts
GSK wins FDA approval to extend Arexvy RSV vaccine to at-risk adults aged 18 to 49, opening 21 million-strong US market
FDA expands Arexvy approval to at-risk adults 18-49, opening 21M-strong US market. Read what this means for GSK, Pfizer, Moderna, and the RSV vaccine landscape.
Can Sanofi turn molecular clamp technology into a global respiratory vaccine platform beyond RSV?
Can Sanofi turn Vicebio’s molecular clamp tech into a global respiratory vaccine platform? Analysts see multi-pathogen potential beyond RSV by 2030.
How much could Vicebio’s $1.15bn acquisition add to Sanofi’s RSV market share by 2030?
Can Sanofi’s $1.15B Vicebio deal help it win 10% of the RSV market by 2030? Analysts weigh in on how combination vaccines could change respiratory care.
What makes molecular clamp technology attractive for future combination respiratory vaccines?
Can molecular clamp technology make combination respiratory vaccines more practical than mRNA? Learn how Sanofi plans to use it for multi-pathogen protection.
Will Vicebio’s VXB-241 and VXB-251 give Sanofi an edge in older adult respiratory protection?
Can Sanofi’s VXB-241 and VXB-251 vaccines protect older adults better than single-pathogen RSV shots? Explore how they could reshape respiratory care.
Can Sanofi’s molecular clamp bet with Vicebio challenge mRNA leaders in respiratory vaccines?
Can Sanofi’s $1.15B Vicebio deal challenge Pfizer and Moderna’s mRNA RSV dominance? Explore how molecular clamp vaccines could change respiratory protection.
FDA extends approval for GSK’s RSV vaccine, AREXVY, to adults aged 50-59 at increased risk
The U.S. Food and Drug Administration (FDA) has officially broadened the age indication for GSK plc’s (LSE/NYSE: GSK)…